You are now leaving www.amvuttrahcp.com.
You are now being directed to another Alnylam website.
Proceed Cancel
Cardiomyopathy is a common manifestation of ATTR (ATTR‑CM)
that may lead to heart failure.
Polyneuropathy, musculoskeletal manifestations, and other symptoms may also present11,13,17
Either type of ATTR can have a heterogeneous symptom presentation.8
Unexplained left ventricular wall thickening in the absence of hypertension, HFpEF in combination with other noncardiac red-flag symptoms, conduction system disease/atrial fibrillation, intolerance to common CV/HF medications, elevated NT-proBNP20-25
Length-dependent neuropathic pain and weakness, altered sensation, difficulty walking, orthostatic hypotension, recurrent urinary tract infections, sexual dysfunction, sweating abnormalities, and urinary retention2
History of musculoskeletal symptoms (eg, bilateral carpal tunnel syndrome, lumbar spinal stenosis, or biceps tendon rupture), past orthopedic surgery21,22
Diarrhea, constipation, nausea, vomiting, unintentional weight loss2
AMVUTTRA does not treat all of the symptoms of ATTR. AMVUTTRA is approved to treat ATTR-CM and hATTR-PN in adults.
ATTR=transthyretin amyloidosis; ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; CV=cardiovascular; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated amyloidosis; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; NT‑proBNP=N-terminal prohormone of brain-type natriuretic peptide; TTR=transthyretin.
Reduced Serum Vitamin A Levels and Recommended Supplementation
AMVUTTRA treatment leads to a decrease in serum vitamin A levels.
Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.
Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).
Adverse Reactions
In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).
In a study of patients with ATTR-CM, no new safety issues were identified.
AMVUTTRA® (vutrisiran) is indicated for the treatment of the:
For additional information about AMVUTTRA, please see the full Prescribing Information .
IMPORTANT SAFETY INFORMATION AND INDICATIONS